Skip to content
Calculator
Guide

BPC-157 for dogs: no veterinary trials and no dog dose

Last updated: October 28, 2026 · 10 min read · By the Grey Peptides Editorial Board

A professional veterinarian in mask examines a dog indoors during a checkup
Photo by Mikhail Nilov on Pexels
Grey Peptides
Grey Peptides Editorial Board
Every status on this page carries the date it was checked. How we work
Key takeaways
  • No study has tested whether BPC-157 helps dogs with any injury or disease. The published dog data are two laboratory studies from one drug-development group: how fast beagles cleared it, and a toxicology test.
  • There is no veterinary label and no dog dose. A dose that worked in a rat injury model is not a dog dose, and the beagle study showed dogs absorb an intramuscular dose about three times as well as rats.
  • Dogs with arthritis have approved options with trial evidence: FDA-approved veterinary anti-inflammatories, the monthly antibody injection bedinvetmab (Librela) and omega-3-rich diets, within guidelines that also cover weight and exercise. Each drug has side effects a vet can monitor.

Why peptides are being sold for dogs

BPC-157 is sold as a research chemical for people, and owners now ask whether it can help their dogs: whether it works for stiff joints or torn ligaments, what dose to give by weight, and whether other peptides help dog joints. This article sets out what is actually known, as of October 27, 2026.

What is known about BPC-157 in dogs

Two published studies gave BPC-157 to dogs, and neither was a treatment study; both came from one group in Xi'an that had developed a synthetic BPC-157 for possible clinical use. In 2020 it reported preclinical toxicity tests in mice, rats, rabbits and dogs: in repeated-dose testing BPC-157 was well tolerated in dogs, apart from a fall in creatinine at the highest dose that reversed two weeks after dosing stopped 1. In 2022 it measured BPC-157's pharmacokinetics in rats and beagle dogs. After intravenous or intramuscular injection, the intact peptide had an elimination half-life of under 30 minutes in both species, its exposure rose in proportion to dose, and about 45% to 51% of an intramuscular dose reached the bloodstream in dogs, against 14% to 19% in rats. It was rapidly broken down into small fragments and amino acids, excreted mainly in urine and bile 2.

Those studies show how healthy laboratory dogs handle the peptide and that the toxicology programme found no serious toxicity. They do not show that BPC-157 relieves arthritis or heals ligaments, and they say nothing about untested products given at home, because they tested neither. A PubMed search on October 27, 2026 for BPC-157 with dog, dogs, canine or beagle returned three records: these two and a rat study; we found no trial of BPC-157 in dogs with any injury or disease, and no veterinary case series. The healing evidence is from rats and mice. In people, a 2026 systematic review found three small uncontrolled studies with 30 people in all (a knee-pain chart review, an interstitial cystitis pilot and a two-person intravenous safety pilot), all of poor methodological quality, with very low certainty of evidence 3 4 5; that review searched to June 1, 2026. FDA's May 2026 briefing counts five clinical studies in people, about 108 in all, adding two enema studies, one a randomised colitis study known only from a 2005 meeting abstract 6, and a September 2026 report described three dental patients given it with TB-500 and other drugs, without a control group 7. A 2025 orthopaedic systematic review found 35 of its 36 studies were preclinical 8.

Why there is no dog dose

Dose charts for dogs by body weight have no veterinary basis. No study has tested any dose for an effect in dogs, and no veterinary label exists. A dose that produced an effect in a rat injury model is not a dose for a dog: the beagle study found intramuscular bioavailability of 45% to 51% in dogs against 14% to 19% in rats, roughly three times higher 2. The approved dog drugs on this page were tested at their labelled doses in placebo-controlled or comparison trials in client-owned dogs 9 10. Nothing like that has been done for BPC-157, so we do not give, convert or endorse any dose. Our methodology explains our dosing source standard.

TB-500, GHK-Cu and blends for pets

The other peptides sold for dogs have less. A PubMed search on October 27, 2026 for thymosin beta-4, TB-500 or GHK-Cu with dog, dogs or canine returned four records, and only one tested a treatment: in 1996, injections of a tripeptide-copper complex into experimental paw-pad wounds in 12 research dogs left more type-I collagen in the wounds at 14 days than saline 11. That is a wound-healing experiment, not a study of joints, ligaments or pets. We found no dog study of TB-500 or of the healing blends. TB-500 is a fragment, not thymosin beta-4 itself; see our TB-500 entry. Our blends hub explains why no blend has been studied as sold.

BPC-157 is not an FDA-approved animal drug, and it is not approved for people either 8. US rules let a licensed veterinarian use an approved human or animal drug outside its label, but only within a valid veterinarian-client-patient relationship, and FDA's guidance for veterinarians says that compounding an animal drug from bulk drug substances results in an unapproved animal drug 12. A research-labelled vial ordered online is neither an approved drug nor a veterinary prescription; our article on what 'research use only' means covers that label. If you are considering any peptide for a pet, talk to your vet first, and tell them about anything you have already given.

What vets use for arthritis instead

For canine osteoarthritis, international consensus guidelines from the COAST Development Group set out treatment according to the stage of disease, based on evidence and clinical experience 13. FDA lists six NSAIDs approved for dogs to control osteoarthritis pain and inflammation, all prescription-only 14. The table sets the options side by side.

Option for a dog with arthritis painRegulatory status (US)Evidence in dogs
BPC-157Not an approved animal drugA pharmacokinetic study and a toxicology study in laboratory dogs; no trial in dogs with any injury or disease
TB-500, blendsNot approved animal drugsNo published dog studies found
GHK-CuNot an approved animal drugOne 1996 study of injected copper tripeptide in experimental paw-pad wounds in 12 research dogs
Bedinvetmab (Librela), monthly injectionFDA-approved May 5, 2023 (NADA 141-562); label updated February 18, 2025 with post-approval adverse reactionsTwo placebo-controlled field trials and comparisons with meloxicam and grapiprant
Veterinary NSAIDs (carprofen, deracoxib, firocoxib, grapiprant, meloxicam, robenacoxib)FDA-approved for dogs, prescription onlyPrescribed for osteoarthritis pain; gut, kidney and liver side effects to watch for
Weight control, exercise, omega-3-rich dietsNot drugsPart of international staging-based guidelines; a randomised diet trial showed owner-reported gains

FDA says veterinarians often prescribe NSAIDs for dogs with osteoarthritis, and warns that they can cause stomach and intestinal ulcers and perforations, kidney damage and failure, and liver problems, so owners should know the signs to watch for 14. Bedinvetmab, sold as Librela, is a canine antibody against nerve growth factor, given as a monthly injection. In a placebo-controlled trial of 287 dogs, 43.5% achieved owner-assessed treatment success at day 28 on bedinvetmab against 16.9% on placebo 9. In the trial run to support US registration, 272 dogs, success at day 28 was 47.4% against 36.6%, and the number needed to treat fell from 9.3 at day 28 to 4.3 at day 84 with continued monthly dosing 10. A 2025 open-label comparison with meloxicam in 101 dogs found both reduced orthopaedic scores, with a larger but not statistically significant reduction on bedinvetmab, and 4 adverse events on bedinvetmab against 17 on meloxicam, 9 of them gastrointestinal 15.

Bedinvetmab has its own safety story. FDA approved it on May 5, 2023, and on December 16, 2024 its Center for Veterinary Medicine published a 'Dear Veterinarian' letter on reported adverse events including ataxia (loss of coordination), seizures, other neurologic signs, increased thirst and urination, with death (including euthanasia) reported as an outcome in some cases 16. A summary by the Society of Veterinary Hospital Pharmacists records that the label was updated on February 18, 2025 with a post-approval experience section and the advice that clinicians discuss the potential for adverse events with owners before treatment 17. Its benefits were measured in trials, and its reported side effects are tracked and disclosed on the label.

Grapiprant, a daily tablet that FDA lists among the NSAIDs approved for dogs, is approved only for osteoarthritis pain and inflammation 14. In a 2026 double-blind trial in 32 dogs over 20 kg with hip or knee (stifle) arthritis, using force-plate measurements of how much weight the dogs put on their legs, bedinvetmab was non-inferior to grapiprant, with success rates of 68.8% and 56.3% at six weeks, and owners reported improvement with both 18. The point is not that one is best for every dog; it is that these options have been measured in dogs, with objective outcomes, and a vet can choose among them.

Diet matters too. In a randomised, double-blinded trial of 127 dogs with osteoarthritis, a food with 31 times the omega-3 fatty acid content of the control food improved owners' ratings of their dogs' ability to rise and play at 6 weeks and to walk at 12 and 24 weeks, compared with a typical commercial food 19.

Ligament injuries in dogs

Many owners ask about peptides for a dog with a torn cranial cruciate ligament, the canine counterpart of the anterior cruciate ligament in people. Treatment options include conservative management, extracapsular stabilisation and bone-cutting operations such as tibial plateau levelling osteotomy (TPLO) and tibial tuberosity advancement (TTA); a review of small dogs found conservative management likely to mean a longer recovery, around four months on average 20, and a systematic review of 72 surgical studies judged both TPLO and TTA successful, with most of the evidence of low quality 21. No peptide has been tested in dogs with this injury. Our article on peptides for tendon and ligament injuries in people shows how thin the human evidence is; for dogs it does not exist.

Questions to ask your vet

  • What is causing my dog's lameness or pain, and what stage is it at?
  • Which approved treatments suit my dog, given its age, weight, kidney and liver function and other medicines?
  • Would weight loss, a change of diet, physiotherapy or controlled exercise help, and what would a plan look like?
  • What side effects should I watch for with the treatment we choose, and how will we monitor them?
  • I have read about BPC-157 or other peptides. Is there any evidence for them in dogs, and could they interfere with treatment?

The risks of trying it anyway

The orthopaedic review that counted BPC-157's studies warned that adverse effects are possible from unregulated manufacturing, contamination and unknown clinical safety 8; our article on contaminants covers what testing of research peptides has found. The dog toxicology study used the developers' own synthetic peptide in laboratory animals, so it says nothing about what is in a vial bought online 1. And a peptide given in place of a treatment that works can leave a dog in pain longer. If an owner does give something, their vet needs to know, so that it can be considered if the dog becomes unwell.

The bottom line

As of October 27, 2026, there is no evidence that BPC-157 or any research peptide helps dogs with arthritis or injuries, no safety evidence beyond laboratory toxicology of one group's own peptide, and no dog dose. The two dog studies measured how quickly beagles cleared it and how laboratory dogs tolerated it. Dogs with arthritis or injuries have approved treatments with trial evidence and known side effects, and a vet can tailor them to the dog. If the research changes, with a properly designed dog trial of BPC-157, we will update this page. Nothing on this page is veterinary advice or a dose; talk to your veterinarian.

Frequently asked questions

Is BPC-157 safe for dogs?

That is not established. A 2020 preclinical toxicology study by the group developing a synthetic BPC-157 found it well tolerated in laboratory dogs, but no study has tested it in dogs with any condition, or tested products sold online. It is not an approved animal drug.

What is the BPC-157 dosage for dogs by weight?

There is none. No study has tested any dose for an effect in dogs and no veterinary label exists. A dose from a rat injury model does not carry over: dogs absorbed an intramuscular dose about three times as well as rats in the one pharmacokinetic study.

Do peptides help dogs' joints?

No peptide has been tested in dogs with arthritis. Approved options with trial evidence include FDA-approved veterinary NSAIDs, the monthly injection bedinvetmab (Librela) and omega-3-rich diets, within staging-based guidelines.

Is Librela safe?

It beat placebo in field trials and is FDA-approved. On December 16, 2024 FDA wrote to veterinarians about reported adverse events including neurologic signs, and the label added a post-approval experience section on February 18, 2025. Discuss the benefits and risks with your vet.

Sources

  1. Xu, C., et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regul Toxicol Pharmacol, 114, 104665. PMID: 32334036
  2. He, L., et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Front Pharmacol, 13, 1026182. PMID: 36588717
  3. Poolton, J. T., et al. (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthop Belg, 92(3). PMID: 42885452
  4. Lee, E., et al. (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Altern Ther Health Med, 27(4), 8-13. PMID: 34324435
  5. Lee, E., et al. (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Altern Ther Health Med, 31(5), 20-24. PMID: 40131143
  6. U.S. Food and Drug Administration. FDA Evaluation of BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), briefing document for the July 23-24, 2026 Pharmacy Compounding Advisory Committee, dated May 11, 2026: five clinical studies (rectal enemas in 24 healthy subjects; a randomised, placebo-controlled enema study in ulcerative colitis, 53 randomised, reported only as a 2005 meeting abstract, its data judged inadequate to support efficacy or safety; intra-articular injections in 17 people with knee pain; an intravesical injection in 12 with interstitial cystitis; intravenous infusions in 2 healthy subjects), 108 people by its own counts; FDA proposes not adding either substance to the 503A Bulks List. Read October 28, 2026. FDA
  7. Froum, S., et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Front Oral Health, 7, 1907109. PMID: 42876687
  8. Vasireddi, N., et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J, 21(4), 485-495. PMID: 40756949
  9. Corral, M. J., et al. (2021). A prospective, randomized, blinded, placebo-controlled multisite clinical study of bedinvetmab, a canine monoclonal antibody targeting nerve growth factor, in dogs with osteoarthritis. Vet Anaesth Analg, 48(6), 943-955. PMID: 34565678
  10. Michels, G. M., et al. (2023). A prospective, randomized, double-blind, placebo-controlled multisite, parallel-group field study in dogs with osteoarthritis conducted in the United States of America evaluating bedinvetmab, a canine anti-nerve growth factor monoclonal antibody. Vet Anaesth Analg, 50(5), 446-458. PMID: 37541934
  11. Swaim, S. F., et al. (1996). Effect of locally injected medications on healing of pad wounds in dogs. Am J Vet Res, 57(3), 394-9. PMID: 8669775
  12. U.S. Food and Drug Administration, Center for Veterinary Medicine. The Ins and Outs of Extra-Label Drug Use in Animals: A Resource for Veterinarians. Content current as of June 2, 2023; re-read October 27, 2026. FDA
  13. Cachon, T., et al. (2023). COAST Development Group's international consensus guidelines for the treatment of canine osteoarthritis. Front Vet Sci, 10, 1137888. PMID: 37601753
  14. U.S. Food and Drug Administration, Center for Veterinary Medicine. Get the Facts about Pain Relievers for Pets (FDA-approved NSAIDs for dogs; side effects). Content current as of September 29, 2022; re-read October 27, 2026. FDA
  15. Innes, J. F., et al. (2025). A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci, 12, 1502218. PMID: 40196808
  16. U.S. Food and Drug Administration, Center for Veterinary Medicine. Dear Veterinarian Letter Notifying Veterinarians about Adverse Events Reported in Dogs Treated with Librela (bedinvetmab injection). Content current as of December 16, 2024; re-read October 27, 2026. FDA
  17. Society of Veterinary Hospital Pharmacists (vetmeds.org), a professional society's summary. Labeling update alert: Librela (bedinvetmab injection), NADA 141-562, label updated February 18, 2025. Re-read October 27, 2026.
  18. Enomoto, M., et al. (2026). A noninferiority trial evaluating the efficacy of bedinvetmab compared to grapiprant for osteoarthritis-pain in dogs using force plate gait analysis. Sci Rep, 16(1). PMID: 41667566
  19. Roush, J. K., et al. (2010). Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. J Am Vet Med Assoc, 236(1), 59-66. PMID: 20043800
  20. Brioschi, V., et al. (2021). Cranial cruciate ligament rupture in small dogs (<15 kg): a narrative literature review. J Small Anim Pract, 62(12), 1037-1050. PMID: 34269419
  21. Wemmers, A. C., et al. (2022). Surgical treatment of cranial cruciate ligament disease in dogs using Tibial Plateau Leveling Osteotomy or Tibial Tuberosity Advancement-A systematic review with a meta-analytic approach. Front Vet Sci, 9, 1004637. PMID: 36532339

Educational information, not medical advice. Each dose in this guide names its source, an approved label or a published study. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose.

All articles

New guides and rule changes, by email

One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.

We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead